Literature DB >> 24906973

Evaluation of an integrated care program for schizophrenia: concept and study design.

L Kerkemeyer1, S Mostardt, J Biermann, J Wasem, A Neumann, A Walendzik, R Jahn, C Bartels, P Falkai, W Brannath, V Breunig-Lyriti, B Mester, J Timm, T Wobrock.   

Abstract

Concept and design of an independent scientific evaluation of different pathways of care for schizophrenia patients in Germany with respect to effectiveness and efficiency are presented. In this prospective, observational study, schizophrenia patients receiving an integrated care treatment, the intervention group (IG), are compared with patients under routine care conditions treated by the same physician (first control group, CG 1). A second control group (CG 2) of patients treated by office-based psychiatrists not participating in the integrated care program will be recruited and their data compared with the two other groups. The total amount of psychiatric hospital days after 12 months is defined as primary outcome parameter. Secondary outcome parameters comprise the frequency of psychiatric inpatient readmissions, severity of schizophrenia symptoms, remission rates and quality of life. Patients undergo assessments at baseline, month 6 and 12 using standardized and experimental questionnaires. Routine data of a regional German social health insurance fund complement information on included patients. Additionally, a cost-effectiveness and cost-utility analysis will be performed. Until now, 137 psychiatrists included 980 patients in the integrated care project in Lower Saxony, Germany, and 47 psychiatrists (IG and both CGs) are willing to participate in the independent evaluation. For the first time, a prospective observational controlled evaluation study of a countrywide integrated care project planning to recruit 500 schizophrenia patients has started using comprehensive assessments as well as routine data of a social health insurance fund.

Entities:  

Mesh:

Year:  2014        PMID: 24906973     DOI: 10.1007/s00406-014-0508-6

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  18 in total

1.  A meta-analysis of the effectiveness of mental health case management over 20 years.

Authors:  S J Ziguras; G W Stuart
Journal:  Psychiatr Serv       Date:  2000-11       Impact factor: 3.084

2.  [The standardized assessment of the need for treatment and support in severe mental illness: the development and testing of the German version of the Camberwell assessment of Need-EU].

Authors:  R Kilian; S Bernert; H Matschinger; C Mory; C Roick; M C Angermeyer
Journal:  Psychiatr Prax       Date:  2001-10

3.  Outcome of case management based on the strengths model compared to standard care. A randomised controlled trial.

Authors:  Tommy Björkman; Lars Hansson; Mikael Sandlund
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2002-04       Impact factor: 4.328

4.  Assertive community treatment as part of integrated care versus standard care: a 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial).

Authors:  Martin Lambert; Thomas Bock; Daniel Schöttle; Dietmar Golks; Klara Meister; Liz Rietschel; Alexandra Bussopulos; Marietta Frieling; Michael Schödlbauer; Marc Burlon; Christian G Huber; Gunda Ohm; Manoshi Pakrasi; Michael Sadre Chirazi-Stark; Dieter Naber; Benno G Schimmelmann
Journal:  J Clin Psychiatry       Date:  2010-03-23       Impact factor: 4.384

5.  The Calgary Depression Rating Scale for Schizophrenia: development and interrater reliability of a German version (CDSS-G).

Authors:  M J Müller; P Marx-Dannigkeit; R Schlösser; H Wetzel; D Addington; O Benkert
Journal:  J Psychiatr Res       Date:  1999 Sep-Oct       Impact factor: 4.791

6.  Cost of disorders of the brain in Europe 2010.

Authors:  Anders Gustavsson; Mikael Svensson; Frank Jacobi; Christer Allgulander; Jordi Alonso; Ettore Beghi; Richard Dodel; Mattias Ekman; Carlo Faravelli; Laura Fratiglioni; Brenda Gannon; David Hilton Jones; Poul Jennum; Albena Jordanova; Linus Jönsson; Korinna Karampampa; Martin Knapp; Gisela Kobelt; Tobias Kurth; Roselind Lieb; Mattias Linde; Christina Ljungcrantz; Andreas Maercker; Beatrice Melin; Massimo Moscarelli; Amir Musayev; Fiona Norwood; Martin Preisig; Maura Pugliatti; Juergen Rehm; Luis Salvador-Carulla; Brigitte Schlehofer; Roland Simon; Hans-Christoph Steinhausen; Lars Jacob Stovner; Jean-Michel Vallat; Peter Van den Bergh; Peter Van den Bergh; Jim van Os; Pieter Vos; Weili Xu; Hans-Ulrich Wittchen; Bengt Jönsson; Jes Olesen
Journal:  Eur Neuropsychopharmacol       Date:  2011-09-15       Impact factor: 4.600

7.  Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol.

Authors:  S L Tunis; T W Croghan; D K Heilman; B M Johnstone; R L Obenchain
Journal:  Med Care       Date:  1999-07       Impact factor: 2.983

Review 8.  Remission in schizophrenia: proposed criteria and rationale for consensus.

Authors:  Nancy C Andreasen; William T Carpenter; John M Kane; Robert A Lasser; Stephen R Marder; Daniel R Weinberger
Journal:  Am J Psychiatry       Date:  2005-03       Impact factor: 18.112

9.  Prevention of rehospitalization in schizophrenia: results of an integrated care project in Germany.

Authors:  Christian Schmidt-Kraepelin; Birgit Janssen; Wolfgang Gaebel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-11       Impact factor: 5.270

Review 10.  Use of intensive case management to reduce time in hospital in people with severe mental illness: systematic review and meta-regression.

Authors:  Tom Burns; Jocelyn Catty; Michael Dash; Chris Roberts; Austin Lockwood; Max Marshall
Journal:  BMJ       Date:  2007-07-13
View more
  4 in total

1.  Schizophrenia spectrum and related neuropathology.

Authors:  Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-03       Impact factor: 5.270

2.  Negative symptoms, anxiety, and depression as mechanisms of change of a 12-month trial of assertive community treatment as part of integrated care in patients with first- and multi-episode schizophrenia spectrum disorders (ACCESS I trial).

Authors:  Stefanie J Schmidt; Matthias Lange; Daniel Schöttle; Anne Karow; Benno G Schimmelmann; Martin Lambert
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-05-24       Impact factor: 5.270

3.  Effectiveness and cost-effectiveness of an integrated care program for schizophrenia: an analysis of routine data.

Authors:  Linda Kerkemeyer; Jürgen Wasem; Anja Neumann; Werner Brannath; Benjamin Mester; Jürgen Timm; Thomas Wobrock; Claudia Bartels; Peter Falkai; Janine Biermann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-08-08       Impact factor: 5.270

4.  An Integrated Care Initiative to Improve Patient Outcome in Schizophrenia.

Authors:  Norbert Mayer-Amberg; Rainer Woltmann; Stefanie Walther
Journal:  Front Psychiatry       Date:  2016-01-08       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.